vs

Side-by-side financial comparison of Arcosa, Inc. (ACA) and Penumbra Inc (PEN). Click either name above to swap in a different company.

Arcosa, Inc. is the larger business by last-quarter revenue ($716.7M vs $385.4M, roughly 1.9× Penumbra Inc). Penumbra Inc runs the higher net margin — 12.3% vs 7.3%, a 5.0% gap on every dollar of revenue. On growth, Penumbra Inc posted the faster year-over-year revenue change (22.1% vs 7.6%). Penumbra Inc produced more free cash flow last quarter ($68.0M vs $55.8M). Over the past eight quarters, Penumbra Inc's revenue compounded faster (17.6% CAGR vs 9.4%).

Arcosa, Inc. is a provider of infrastructure-related products and solutions operating across three core segments: construction, energy, and transportation. It offers products including utility structures, construction aggregates, and transportation components, primarily serving customers across the North American market to support critical infrastructure development projects.

Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.

ACA vs PEN — Head-to-Head

Bigger by revenue
ACA
ACA
1.9× larger
ACA
$716.7M
$385.4M
PEN
Growing faster (revenue YoY)
PEN
PEN
+14.6% gap
PEN
22.1%
7.6%
ACA
Higher net margin
PEN
PEN
5.0% more per $
PEN
12.3%
7.3%
ACA
More free cash flow
PEN
PEN
$12.3M more FCF
PEN
$68.0M
$55.8M
ACA
Faster 2-yr revenue CAGR
PEN
PEN
Annualised
PEN
17.6%
9.4%
ACA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACA
ACA
PEN
PEN
Revenue
$716.7M
$385.4M
Net Profit
$52.1M
$47.3M
Gross Margin
22.9%
68.0%
Operating Margin
11.0%
15.4%
Net Margin
7.3%
12.3%
Revenue YoY
7.6%
22.1%
Net Profit YoY
776.6%
40.6%
EPS (diluted)
$1.06
$1.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACA
ACA
PEN
PEN
Q4 25
$716.7M
$385.4M
Q3 25
$797.8M
$354.7M
Q2 25
$736.9M
$339.5M
Q1 25
$632.0M
$324.1M
Q4 24
$666.2M
$315.5M
Q3 24
$640.4M
$301.0M
Q2 24
$664.7M
$299.4M
Q1 24
$598.6M
$278.7M
Net Profit
ACA
ACA
PEN
PEN
Q4 25
$52.1M
$47.3M
Q3 25
$73.0M
$45.9M
Q2 25
$59.7M
$45.3M
Q1 25
$23.6M
$39.2M
Q4 24
$-7.7M
$33.7M
Q3 24
$16.6M
$29.5M
Q2 24
$45.6M
$-60.2M
Q1 24
$39.2M
$11.0M
Gross Margin
ACA
ACA
PEN
PEN
Q4 25
22.9%
68.0%
Q3 25
24.1%
67.8%
Q2 25
22.5%
66.0%
Q1 25
19.8%
66.6%
Q4 24
19.3%
66.8%
Q3 24
21.3%
66.5%
Q2 24
20.8%
54.4%
Q1 24
18.6%
65.0%
Operating Margin
ACA
ACA
PEN
PEN
Q4 25
11.0%
15.4%
Q3 25
14.1%
13.8%
Q2 25
12.9%
12.0%
Q1 25
8.8%
12.4%
Q4 24
6.5%
13.6%
Q3 24
5.3%
11.7%
Q2 24
10.1%
-27.0%
Q1 24
8.9%
4.3%
Net Margin
ACA
ACA
PEN
PEN
Q4 25
7.3%
12.3%
Q3 25
9.2%
12.9%
Q2 25
8.1%
13.3%
Q1 25
3.7%
12.1%
Q4 24
-1.2%
10.7%
Q3 24
2.6%
9.8%
Q2 24
6.9%
-20.1%
Q1 24
6.5%
3.9%
EPS (diluted)
ACA
ACA
PEN
PEN
Q4 25
$1.06
$1.20
Q3 25
$1.48
$1.17
Q2 25
$1.22
$1.15
Q1 25
$0.48
$1.00
Q4 24
$-0.16
$0.88
Q3 24
$0.34
$0.75
Q2 24
$0.93
$-1.55
Q1 24
$0.80
$0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACA
ACA
PEN
PEN
Cash + ST InvestmentsLiquidity on hand
$214.6M
$186.9M
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$2.6B
$1.4B
Total Assets
$5.0B
$1.8B
Debt / EquityLower = less leverage
0.57×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACA
ACA
PEN
PEN
Q4 25
$214.6M
$186.9M
Q3 25
$220.0M
$321.0M
Q2 25
$189.7M
$421.8M
Q1 25
$167.9M
$376.1M
Q4 24
$187.3M
$324.4M
Q3 24
$756.8M
$280.5M
Q2 24
$103.7M
$288.3M
Q1 24
$176.5M
$223.1M
Total Debt
ACA
ACA
PEN
PEN
Q4 25
$1.5B
Q3 25
$1.6B
Q2 25
$1.7B
Q1 25
$1.7B
Q4 24
$1.7B
Q3 24
$1.2B
Q2 24
$699.9M
Q1 24
$600.6M
Stockholders' Equity
ACA
ACA
PEN
PEN
Q4 25
$2.6B
$1.4B
Q3 25
$2.6B
$1.4B
Q2 25
$2.5B
$1.3B
Q1 25
$2.5B
$1.2B
Q4 24
$2.4B
$1.2B
Q3 24
$2.4B
$1.1B
Q2 24
$2.4B
$1.2B
Q1 24
$2.4B
$1.2B
Total Assets
ACA
ACA
PEN
PEN
Q4 25
$5.0B
$1.8B
Q3 25
$5.1B
$1.7B
Q2 25
$5.0B
$1.7B
Q1 25
$4.9B
$1.6B
Q4 24
$4.9B
$1.5B
Q3 24
$4.4B
$1.5B
Q2 24
$3.8B
$1.5B
Q1 24
$3.7B
$1.6B
Debt / Equity
ACA
ACA
PEN
PEN
Q4 25
0.57×
Q3 25
0.61×
Q2 25
0.67×
Q1 25
0.68×
Q4 24
0.69×
Q3 24
0.51×
Q2 24
0.29×
Q1 24
0.25×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACA
ACA
PEN
PEN
Operating Cash FlowLast quarter
$120.0M
$86.5M
Free Cash FlowOCF − Capex
$55.8M
$68.0M
FCF MarginFCF / Revenue
7.8%
17.7%
Capex IntensityCapex / Revenue
9.0%
4.8%
Cash ConversionOCF / Net Profit
2.30×
1.83×
TTM Free Cash FlowTrailing 4 quarters
$175.5M
$174.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACA
ACA
PEN
PEN
Q4 25
$120.0M
$86.5M
Q3 25
$160.6M
$58.3M
Q2 25
$61.2M
$44.9M
Q1 25
$-700.0K
$49.0M
Q4 24
$248.2M
$51.1M
Q3 24
$135.0M
$56.5M
Q2 24
$38.3M
$22.6M
Q1 24
$80.5M
$38.3M
Free Cash Flow
ACA
ACA
PEN
PEN
Q4 25
$55.8M
$68.0M
Q3 25
$121.0M
$42.0M
Q2 25
$33.4M
$29.4M
Q1 25
$-34.7M
$35.5M
Q4 24
$194.9M
$45.7M
Q3 24
$100.6M
$51.0M
Q2 24
$-9.3M
$18.1M
Q1 24
$26.1M
$32.5M
FCF Margin
ACA
ACA
PEN
PEN
Q4 25
7.8%
17.7%
Q3 25
15.2%
11.8%
Q2 25
4.5%
8.7%
Q1 25
-5.5%
11.0%
Q4 24
29.3%
14.5%
Q3 24
15.7%
16.9%
Q2 24
-1.4%
6.0%
Q1 24
4.4%
11.7%
Capex Intensity
ACA
ACA
PEN
PEN
Q4 25
9.0%
4.8%
Q3 25
5.0%
4.6%
Q2 25
3.8%
4.6%
Q1 25
5.4%
4.2%
Q4 24
8.0%
1.7%
Q3 24
5.4%
1.8%
Q2 24
7.2%
1.5%
Q1 24
9.1%
2.1%
Cash Conversion
ACA
ACA
PEN
PEN
Q4 25
2.30×
1.83×
Q3 25
2.20×
1.27×
Q2 25
1.03×
0.99×
Q1 25
-0.03×
1.25×
Q4 24
1.52×
Q3 24
8.13×
1.91×
Q2 24
0.84×
Q1 24
2.05×
3.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACA
ACA

Engineered Structures$301.1M42%
Total Construction Materials$276.8M39%
Specialty Materials And Asphalt$110.2M15%
Construction Site Support$28.6M4%

PEN
PEN

Thrombectomy$254.7M66%
Other$130.7M34%

Related Comparisons